VieCure has been at the forefront of oncology treatment planning, and with its recent fund will bring its AI platform to clinics, assisting them with the growing demands of precision medicine.
Community oncology clinics treat more than 80% of cancer patients. Yet many are struggling to keep pace with the “explosion” of precision medicine and complex genomic data. VieCure aims to bridge this widening gap.
Armed with $43 million in new funding led by Danaher co-founder Mitch Rales and Northpond Ventures, the health-tech innovator is scaling its AI-powered “Halo Intelligence” platform.
By integrating real-time clinical decision support directly into the workflow, VieCure is working to decentralize elite-level cancer care. It is bringing the highest caliber of precision medicine from academic centers into local neighborhoods where patients need it most.
For any health-tech platform selling into clinics, several factors are key. They include adoption depends on the quality of implementation, training, and support as much as features.
VieCure’s funding round will be used to expand its AI-powered oncology platform and grow its national footprint of community clinics. The company frames it as a step toward “democratizing access to precision medicine in community cancer care practices.”
At the center of the raise is a notable mix of healthcare and operational leadership: Mitch Rales, co-founder of Danaher, is joining VieCure’s board—along with Howard “Skip” Burris III, M.D., a past president of the American Society of Clinical Oncology (ASCO).
Durable Capital Partners, Socium Ventures (backed by Cox Enterprises), and Sator Grove Holdings also participated in the funding.
CEO MichaelPower described the raise as a catalyst: “This investment marks a pivotal moment in our mission to transform how cancer care is delivered to patients everywhere,” he said. He emphasized that oncologists already use VieCure’s platform to “personalize treatment” and connect patients to therapies “at the right time.”
Northpond Ventures founder and CEO Michael Rubin, M.D., Ph.D., CFA pointed to VieCure’s role in standardizing quality across community settings: “As the clinical and operational backbone for cancer clinics, VieCure is democratizing access to the highest caliber cancer care in community settings.”
Precision medicine is advancing faster than workflows
VieCure’s press release describes a widening gap: cancer care is becoming more personalized and protocol-rich, but community clinics already burdened struggle to keep pace with adoption.
According to the company, as the complexity of delivering precision medicine grows, two risks emerge:
- Patient outcomes may suffer if practices can’t adopt or keep up with evolving protocols.
- Practice stability may be pressured when the operational workload becomes harder to sustain.
That’s the opening VieCure is targeting: help clinics deliver modern, evidence-based oncology care without adding friction for clinicians.
What VieCure is building: Halo Intelligence at the point of care
VieCure’s flagship platform, Halo Intelligence™, is described as an AI-powered clinical decision support system combined with a purpose-built oncology EMR.
The goal is straightforward: ensure clinicians have “real-time access to everything they need” to deliver the right treatment to each patient—while reducing workflow drag.
Halo combines structured patient data, artificial intelligence, and workflow automation.
Dr. Burris, now a VieCure board member, positioned this category of technology as essential to the next phase of oncology: “The future of cancer care depends on tools that assist in day-to-day workflows” and make it easier “to deliver the right therapy at the right time.”
He added that VieCure helps practices “reduce clinician burden,” stay aligned with evolving standards, and focus on timely care.
Real-world usage
VieCure currently manages care for nearly 30,000 patients across a growing national network of practice locations.
The company also reported performance improvements from clinics using its platform, including:
- an increase in the rate of tumor sequencing
- an increase in guideline-compliant treatment plans, and
- increased oncologist capacity and workflow productivity
Ashvini Sengar, M.D., President and Chief Medical Officer of Alabama Cancer Care, stated, “VieCure has fundamentally changed how we care for patients.”
Key Partnership in Place
“I’m honored to join the board,” Rales said, adding that his firm New Bearing will partner, “to instill in VieCure the highest level of operating capabilities.” He framed the commitment as enduring: “We are committed to VieCure for the long-term.”
As VieCure ties its growth plan to operating system rigor, the company said it is partnering with New Bearing, a business-building firm, to implement the New Bearing Foundational Business System.
A Promising Future
VieCure’s thesis is direct. Community oncology clinics shouldn’t have to choose between keeping up with precision medicine and maintaining sustainable operations.
As the company increases the number of community practice locations and deepens its penetration in existing networks, it will bring a range of benefits.
With $43 million in fresh funding and high-profile operational and clinical leaders joining the effort, the company is betting it can help make “highest caliber” cancer care more available, where most patients actually receive it.
